ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dalmelitinib

Also written as “HS-10241” and “HS-10241+ Almonertinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma, led by 2 companies.

Drug pageC-Met Inhibitor HS-10241: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 24, 20237 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Groupits history only62 open or runningphase 3since Oct 24, 2023Nov 11, 2016none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since Apr 29, 2016Apr 29, 2016none ahead
  • Named in Hansoh Pharmaceutical Group’s own pipeline as Dalmelitinib (HS-10241), phase 4, as of Aug 26, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02759640 · 7 enrolled · Australia
  2. Jul 21, 2022Named dalmelitinibINNProposed as its International Nonproprietary Name in WHO's List 127 · before, HS-10241

TargetBeta

“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal…”NCIt, read by Claude
“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

The one study Jiangsu HengRui Medicine leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02759640Neoplasms · Australia1CompletedMar 20187

How it is read

Names in the registry

  • “HS-10241”, 6 entries
  • “HS-10241+ Almonertinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.